Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial

Robert J. Anderson; Gideon D. Bahn; Thomas E. Moritz; Derrick Kaufman; Carlos Abraira; William Duckworth

doi:10.2337/dc10-1420

Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial

Robert J. Anderson, Gideon D. Bahn, Thomas E. Moritz, Derrick Kaufman, Carlos Abraira, William Duckworth

Research output: Contribution to journal › Article › peer-review

65 Scopus citations

Abstract

OBJECTIVE - Blood pressure ranges associated with cardiovascular disease (CVD) events in advanced type 2 diabetes are not clear. Our objective was to determine whether baseline and follow-up (On-Study) systolic blood pressure (SBP), diastolic blood pressure (DBP), and SBP combined with DBP predict CVD events in the Veterans Affairs Diabetes Trial (VADT). RESEARCH DESIGN AND METHODS - Participants in the VADT (n = 1,791) with hypertension received stepped treatment to maintain blood pressure below the target of 130/80 mmHg in standard and intensive glycemic treatment groups. Blood pressure levels of all subjects at baseline and On-Study were analyzed to detect associations with CVD risk. The primary outcome was the time from randomization to the first occurrence of myocardial infarction, stroke, congestive heart failure, surgery for vascular disease, inoperable coronary disease, amputation for ischemic gangrene, or CVD death. RESULTS - Separated SBP ≥140 mmHg had significant risk at baseline (hazards ratio [HR] 1.508, P

Original language	English (US)
Pages (from-to)	34-38
Number of pages	5
Journal	Diabetes care
Volume	34
Issue number	1
DOIs	https://doi.org/10.2337/dc10-1420
State	Published - Jan 2011
Externally published	Yes

All Science Journal Classification (ASJC) codes

Internal Medicine
Endocrinology, Diabetes and Metabolism
Advanced and Specialized Nursing

Access to Document

10.2337/dc10-1420

Fingerprint Dive into the research topics of 'Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial'. Together they form a unique fingerprint.

Cite this

@article{b60f3f0685724f959c2f02a5a5b77b9d,

title = "Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial",

abstract = "OBJECTIVE - Blood pressure ranges associated with cardiovascular disease (CVD) events in advanced type 2 diabetes are not clear. Our objective was to determine whether baseline and follow-up (On-Study) systolic blood pressure (SBP), diastolic blood pressure (DBP), and SBP combined with DBP predict CVD events in the Veterans Affairs Diabetes Trial (VADT). RESEARCH DESIGN AND METHODS - Participants in the VADT (n = 1,791) with hypertension received stepped treatment to maintain blood pressure below the target of 130/80 mmHg in standard and intensive glycemic treatment groups. Blood pressure levels of all subjects at baseline and On-Study were analyzed to detect associations with CVD risk. The primary outcome was the time from randomization to the first occurrence of myocardial infarction, stroke, congestive heart failure, surgery for vascular disease, inoperable coronary disease, amputation for ischemic gangrene, or CVD death. RESULTS - Separated SBP ≥140 mmHg had significant risk at baseline (hazards ratio [HR] 1.508, P",

author = "Anderson, {Robert J.} and Bahn, {Gideon D.} and Moritz, {Thomas E.} and Derrick Kaufman and Carlos Abraira and William Duckworth",

year = "2011",

month = jan,

doi = "10.2337/dc10-1420",

language = "English (US)",

volume = "34",

pages = "34--38",

journal = "Diabetes Care",

issn = "1935-5548",

publisher = "American Diabetes Association Inc.",

number = "1",

}

TY - JOUR

T1 - Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial

AU - Anderson, Robert J.

AU - Bahn, Gideon D.

AU - Moritz, Thomas E.

AU - Kaufman, Derrick

AU - Abraira, Carlos

AU - Duckworth, William

PY - 2011/1

Y1 - 2011/1

N2 - OBJECTIVE - Blood pressure ranges associated with cardiovascular disease (CVD) events in advanced type 2 diabetes are not clear. Our objective was to determine whether baseline and follow-up (On-Study) systolic blood pressure (SBP), diastolic blood pressure (DBP), and SBP combined with DBP predict CVD events in the Veterans Affairs Diabetes Trial (VADT). RESEARCH DESIGN AND METHODS - Participants in the VADT (n = 1,791) with hypertension received stepped treatment to maintain blood pressure below the target of 130/80 mmHg in standard and intensive glycemic treatment groups. Blood pressure levels of all subjects at baseline and On-Study were analyzed to detect associations with CVD risk. The primary outcome was the time from randomization to the first occurrence of myocardial infarction, stroke, congestive heart failure, surgery for vascular disease, inoperable coronary disease, amputation for ischemic gangrene, or CVD death. RESULTS - Separated SBP ≥140 mmHg had significant risk at baseline (hazards ratio [HR] 1.508, P

AB - OBJECTIVE - Blood pressure ranges associated with cardiovascular disease (CVD) events in advanced type 2 diabetes are not clear. Our objective was to determine whether baseline and follow-up (On-Study) systolic blood pressure (SBP), diastolic blood pressure (DBP), and SBP combined with DBP predict CVD events in the Veterans Affairs Diabetes Trial (VADT). RESEARCH DESIGN AND METHODS - Participants in the VADT (n = 1,791) with hypertension received stepped treatment to maintain blood pressure below the target of 130/80 mmHg in standard and intensive glycemic treatment groups. Blood pressure levels of all subjects at baseline and On-Study were analyzed to detect associations with CVD risk. The primary outcome was the time from randomization to the first occurrence of myocardial infarction, stroke, congestive heart failure, surgery for vascular disease, inoperable coronary disease, amputation for ischemic gangrene, or CVD death. RESULTS - Separated SBP ≥140 mmHg had significant risk at baseline (hazards ratio [HR] 1.508, P

UR - http://www.scopus.com/inward/record.url?scp=79951713554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951713554&partnerID=8YFLogxK

U2 - 10.2337/dc10-1420

DO - 10.2337/dc10-1420

M3 - Article

C2 - 21059830

AN - SCOPUS:79951713554

VL - 34

SP - 34

EP - 38

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 1

ER -